4.4 Article

A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations

期刊

FUTURE ONCOLOGY
卷 18, 期 30, 页码 3377-3387

出版社

FUTURE MEDICINE LTD
DOI: 10.2217/fon-2022-0305

关键词

advanced solid tumor; clinical trial; Cowden syndrome; germline PTEN mutation; PTEN hamartoma tumor syndrome; PTEN inactivation; TAS-117

类别

资金

  1. Taiho Oncology, Inc. (Princeton, NJ, USA)
  2. Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan)
  3. NIH [CTSA UL1TR00457]
  4. Taiho Oncology, Inc.

向作者/读者索取更多资源

The study aims to test a new oral medication TAS-117 for patients with solid tumors harboring germline PTEN mutations, exploring its potential treatment for rare forms of cancer.
Plain language summary Signaling paths control growth and activities inside cells. Overactivity in these paths can encourage many types of cancers to develop. Tumor suppressor proteins can inhibit cell signals that promote cancer. This protection can be lost if there are errors in any gene coding for a tumor suppressor protein. We are carrying out a clinical study to test TAS-117, a potential new oral medicine, in people who have solid tumors and whose cells have changes in their genes that inactivate a tumor suppressor protein called PTEN. TAS-117 targets part of a signaling path that may be overactive due to loss of PTEN activity. In early research, TAS-117 has shown promising activity against certain tumor types. Our trial will explore if TAS-117 can provide a new treatment for rare forms of cancer where genetic changes have led to a loss of PTEN activity. PTEN acts as a potent tumor suppressor within the PI3K/AKT/mTOR pathway. Germline mutations in the PTEN gene are a hallmark of PTEN hamartoma tumor syndrome, which includes Cowden syndrome, where they appear to elevate lifetime risk of cancer. Targeted AKT directed therapy has been proposed as an effective approach in cancer patients having germline PTEN mutations. The mechanism of action, safety and dosing regimen for the novel allosteric AKT inhibitor TAS-117 have been explored in a phase I study in Japan in which activity was observed against certain tumor types. Here we describe the study protocol of an international, two-part Phase II study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据